- Home
- ORIC vs NUVB Comparison
ORIC vs NUVB Comparison
Compare ORIC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- NUVB
- Stock Information
- Founded
- ORIC 2014
- NUVB 2018
- Country
- ORIC United States
- NUVB United States
- Employees
- ORIC N/A
- NUVB N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- NUVB Health Care
- Exchange
- ORIC Nasdaq
- NUVB Nasdaq
- Market Cap
- ORIC 940.8M
- NUVB 837.0M
- IPO Year
- ORIC 2020
- NUVB N/A
- Fundamental
- Price
- ORIC $10.12
- NUVB $2.23
- Analyst Decision
- ORIC Strong Buy
- NUVB Strong Buy
- Analyst Count
- ORIC 9
- NUVB 6
- Target Price
- ORIC $18.29
- NUVB $7.83
- AVG Volume (30 Days)
- ORIC 1.2M
- NUVB 5.1M
- Earning Date
- ORIC 08-11-2025
- NUVB 08-07-2025
- Dividend Yield
- ORIC N/A
- NUVB N/A
- EPS Growth
- ORIC N/A
- NUVB N/A
- EPS
- ORIC N/A
- NUVB N/A
- Revenue
- ORIC N/A
- NUVB $10,957,000.00
- Revenue This Year
- ORIC N/A
- NUVB $98.78
- Revenue Next Year
- ORIC N/A
- NUVB $489.71
- P/E Ratio
- ORIC N/A
- NUVB N/A
- Revenue Growth
- ORIC N/A
- NUVB N/A
- 52 Week Low
- ORIC $3.90
- NUVB $1.54
- 52 Week High
- ORIC $14.67
- NUVB $3.83
- Technical
- Relative Strength Index (RSI)
- ORIC 43.96
- NUVB 46.97
- Support Level
- ORIC $10.00
- NUVB $2.46
- Resistance Level
- ORIC $11.62
- NUVB $2.76
- Average True Range (ATR)
- ORIC 0.63
- NUVB 0.15
- MACD
- ORIC -0.24
- NUVB -0.01
- Stochastic Oscillator
- ORIC 20.68
- NUVB 21.32
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.